Story
Telix Pharma Shares Surge 12% on FDA Approval of Brain Cancer Imaging Agent
Shares in Telix Pharmaceuticals surged as much as 12% on Monday following the U.S. Food and Drug Administration's (FDA) approval of the company's New Drug Application for Pixclara, a diagnostic imaging agent for brain cancer.
First-in-Class Approval
The FDA's decision makes Pixclara the first and only approved radiopharmaceutical PET imaging agent for glioma, a type of brain cancer. According to a report from Investing.com, this addresses a significant medical need, as glioma accounts for an estimated 24,000 new diagnoses in the United States each year.
The approval provides Telix with a key product in the U.S. oncology market, targeting a specific and serious condition with a newly authorized diagnostic tool.
Strong Financial Backdrop
AdThe regulatory green light comes amid a period of strong operational performance for the company. The stock's rally notably outpaced the broader ASX 200, which faced pressure from declines in technology stocks on the same day.
Telix's recent financial results underscore its growth momentum. For the first half of 2026, the company reported:
- Group revenue of US$477 million, an increase of 22% year-over-year.
- Adjusted EBITDA growth of 146%.
- An improved gross margin of 55%.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.